お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
914378

ゲノム編集サービスの世界市場 - CRISPR:2019年~2030年

Genome Editing Services Market-Focus on CRISPR 2019-2030

出版日: | 発行: Roots Analysis | ページ情報: 英文 290 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.68円
ゲノム編集サービスの世界市場 - CRISPR:2019年~2030年
出版日: 2019年10月31日
発行: Roots Analysis
ページ情報: 英文 290 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界のゲノム編集サービス市場について調査分析し、CRISPRベースのゲノム編集サービスプロバイダーに焦点を当てて、現在の市場情勢、競合分析、主要企業プロファイル、特許分析、助成金分析、先進技術・システム、戦略的パートナーなどについて、体系的な情報を提供しています。

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 現在の市場情勢

  • 概要
  • 全体の市場情勢

第5章 企業の競合分析

  • 概要
  • 調査手法
  • 前提条件と主要パラメーター
  • 競合分析

第6章 企業プロファイル

  • 概要
  • Applied StemCell
  • BioCat
  • Biotools
  • Charles River Laboratories
  • Cobo Scientific
  • Creative Biogene
  • Cyagen Biosciences
  • GeneCopoeia
  • Horizon Discovery
  • NemaMetrix
  • Synbio Technologies
  • Thermo Fisher Scientific

第7章 特許分析

  • 概要
  • 範囲・手法
  • 特許分析
  • 特許ベンチマーキング分析
  • 特許評価分析

第8章 学術助成金分析

  • 概要
  • 範囲・手法
  • 助成金

第9章 ケーススタディ:先進技術/システム・ツール

  • 概要
  • プロバイダー
  • キットプロバイダーのリスト
  • デザインツールプロバイダーのリスト

第10章 潜在的な戦略的パートナー

  • 概要
  • 範囲・手法
  • ゲノム編集サービスプロバイダーの潜在的な戦略的パートナー

第11章 市場予測

  • 概要
  • 調査手法・主な前提条件
  • 市場全体
  • 分布:地域別
  • 分布:サービスのタイプ別、など

第12章 SWOT分析

第13章 エグゼクティブ考察

第14章 付録1:図表データ

第15章 付録2:企業・組織のリスト

図表

List of Figures

  • Figure 3.1. Genome Editing: Historical Milestones
  • Figure 3.2. Genome Editing Techniques
  • Figure 3.3. CRISPR-based Genome Editing Protocol
  • Figure 4.1. CRISPR-based Genome Editing Services: Distribution by Type of Service Offering
  • Figure 4.2. CRISPR-based Genome Editing Services: Distribution by Type of gRNA Format
  • Figure 4.3. CRISPR-based Genome Editing Services: Distribution by Type of Endonuclease
  • Figure 4.4. CRISPR-based Genome Editing Services: Distribution by Type of Cas9 Endonuclease Format
  • Figure 4.5. CRISPR-based Genome Editing Services: Distribution by Type of Cell Line Engineering
  • Figure 4.6. CRISPR-based Genome Editing Services: Distribution by Type of Animal Model Generation
  • Figure 4.7. CRISPR-based Genome Editing Services: Distribution by Availability of CRISPR Libraries
  • Figure 4.8. CRISPR-based Genome Editing Service Providers: Distribution by Year of Establishment
  • Figure 4.9. CRISPR-based Genome Editing Service Providers: Distribution by Company Size
  • Figure 4.10. CRISPR-based Genome Editing Service Providers: Distribution by Geographical Location
  • Figure 4.11. CRISPR-based Genome Editing Service Providers Logo Landscape: Distribution by Company Size and Location of Headquarters
  • Figure 5.1. Company Competitiveness Analysis: Assumptions and Key Parameters
  • Figure 5.2. Company Competitiveness Analysis: Small-sized Players
  • Figure 5.3. Company Competitiveness Analysis: Mid-sized Players
  • Figure 5.4. Company Competitiveness Analysis: Large Players
  • Figure 6.1. Charles River Laboratories: Annual Revenues, 2014-H1 2019 (USD Billion)
  • Figure 6.2. Horizon Discovery: Annual Revenues, 2014-H1 2019 (EUR Million)
  • Figure 6.3. Thermo Fisher Scientific: Annual Revenues, 2014-H1 2019 (USD Million)
  • Figure 7.1. Patent Portfolio: Distribution by Type of Patent
  • Figure 7.2. Patent Portfolio: Distribution by Application Year
  • Figure 7.3. Patent Portfolio: Distribution by Publication Year
  • Figure 7.4. Patent Portfolio: Distribution by Geography
  • Figure 7.5. Patent Portfolio: Distribution by CPC Symbols
  • Figure 7.6. Patent Portfolio: Emerging Focus Areas
  • Figure 7.7. Leading Industry Players: Distribution by Size of Patent Portfolio
  • Figure 7.8. Leading Non-Industry Players: Distribution by Size of Patent Portfolio
  • Figure 7.9. Patent Portfolio: Benchmarking by Patent Characteristics
  • Figure 7.10. Patent Portfolio: Valuation Analysis
  • Figure 8.1. Academic Grant Analysis: Year-wise Trend of Award
  • Figure 8.2. Academic Grant Analysis: Distribution by Amount Awarded
  • Figure 8.3. Academic Grant Analysis: Distribution by Administering Institutes
  • Figure 8.4. Academic Grant Analysis: Distribution by Support Period
  • Figure 8.5. Academic Grant Analysis: Distribution by Funding Mechanism
  • Figure 8.6. Academic Grant Analysis: Distribution by Type of Grant Application
  • Figure 8.7. Academic Grant Analysis: Distribution by Grant Activity
  • Figure 8.8. Academic Grant Analysis: Distribution by Recipient Organization
  • Figure 8.9. Academic Grant Analysis: Regional Distribution of Recipient Organization
  • Figure 8.10. Prominent Project Leaders: Distribution by Number of Grants Awarded
  • Figure 8.11. Academic Grant Analysis: Emerging Focus Areas
  • Figure 8.12. Academic Grant Analysis: Grant Attractiveness Analysis
  • Figure 9.1. CRISPR-based Technology Providers: Distribution by Year of Establishment
  • Figure 9.2. CRISPR-based Technology Providers: Distribution by Company Size
  • Figure 9.3. CRISPR-based Technology Providers: Distribution by Geographical Location and Company Expertise
  • Figure 9.4. CRISPR-based Technology Providers: Distribution by Focus Area
  • Figure 9.5. Key CRISPR-based Technology Providers: Venture Capital Investments (USD Million)
  • Figure 11.1. Overall CRISPR-based Genome Editing Services Market, 2019-2030 (USD Million)
  • Figure 11.2. CRISPR-based Genome Editing Services Market: Distribution by Regions, 2019-2030 (USD Million)
  • Figure 11.3. CRISPR-based Genome Editing Services Market in North America, 2019-2030 (USD Million)
  • Figure 11.4. CRISPR-based Genome Editing Services Market in Europe, 2019-2030 (USD Million)
  • Figure 11.5. CRISPR-based Genome Editing Services Market in Asia Pacific, 2019-2030 (USD Million)
  • Figure 11.6. CRISPR-based Genome Editing Services Market in Rest of the World, 2019-2030 (USD Million)
  • Figure 11.7. CRISPR-based Genome Editing Services Market: Distribution by Type of Services, 2019-2030 (USD Million)
  • Figure 11.8. CRISPR-based Genome Editing Services Market for gRNA Construction, 2019-2030 (USD Million)
  • Figure 11.9. CRISPR-based Genome Editing Services Market for gRNA Construction in North America, 2019-2030 (USD Million)
  • Figure 11.10. CRISPR-based Genome Editing Services Market for gRNA Construction in
  • Figure 11.11. CRISPR-based Genome Editing Services Market for gRNA Construction in Asia Pacific, 2019-2030 (USD Million)
  • Figure 11.12. CRISPR-based Genome Editing Services Market for gRNA Construction in Rest of the World, 2019-2030 (USD Million)
  • Figure 11.13. CRISPR-based Genome Editing Services Market for Cell Line Engineering, 2019-2030 (USD Million)
  • Figure 11.14. CRISPR-based Genome Editing Services Market for Cell Line Engineering in North America, 2019-2030 (USD Million)
  • Figure 11.15. CRISPR-based Genome Editing Services Market for Cell Line Engineering in Europe, 2019-2030 (USD Million)
  • Figure 11.16. CRISPR-based Genome Editing Services Market for Cell Line Engineering in Asia Pacific, 2019-2030 (USD Million)
  • Figure 11.17. CRISPR-based Genome Editing Services Market for Cell Line Engineering in Rest of the World, 2019-2030 (USD Million)
  • Figure 11.18. CRISPR-based Genome Editing Services Market for Animal Model Generation, 2019-2030 (USD Million)
  • Figure 11.19. CRISPR-based Genome Editing Services Market for Animal Model Generation in North America, 2019-2030 (USD Million)
  • Figure 11.20. CRISPR-based Genome Editing Services Market for Animal Model Generation in Europe, 2019-2030 (USD Million)
  • Figure 11.21. CRISPR-based Genome Editing Services Market for Animal Model Generation in Asia Pacific, 2019-2030 (USD Million)
  • Figure 11.22. CRISPR-based Genome Editing Services Market for Animal Model Generation in Rest of the World, 2019-2030 (USD Million)
  • Figure 11.23. CRISPR-based Genome Editing Services Market: Distribution by Type of Cell Line, 2019-2030 (USD Million)
  • Figure 11.24. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines, 2019-2030 (USD Million)
  • Figure 11.25. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines in North America, 2019-2030 (USD Million)
  • Figure 11.26. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines in Europe, 2019-2030 (USD Million)
  • Figure 11.27. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines in Asia Pacific, 2019-2030 (USD Million)
  • Figure 11.28. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines in Rest of the World, 2019-2030 (USD Million)
  • Figure 11.29. CRISPR-based Genome Editing Services Market for Microbial Cell Lines, 2019-2030 (USD Million)
  • Figure 11.30. CRISPR-based Genome Editing Services Market for Microbial Cell Lines in North America, 2019-2030 (USD Million)
  • Figure 11.31. CRISPR-based Genome Editing Services Market for Microbial Cell Lines in Europe, 2019-2030 (USD Million)
  • Figure 11.32. CRISPR-based Genome Editing Services Market for Microbial Cell Lines in Asia Pacific, 2019-2030 (USD Million)
  • Figure 11.33. CRISPR-based Genome Editing Services Market for Microbial Cell Lines in Rest of the World, 2019-2030 (USD Million)
  • Figure 11.34. CRISPR-based Genome Editing Services Market for Other Cell Lines, 2019-2030 (USD Million)
  • Figure 11.35. CRISPR-based Genome Editing Services Market for Other Cell Lines in North America, 2019-2030 (USD Million)
  • Figure 11.36. CRISPR-based Genome Editing Services Market for Other Cell Lines in Europe, 2019-2030 (USD Million)
  • Figure 11.37. CRISPR-based Genome Editing Services Market for Other Cell Lines in Asia Pacific, 2019-2030 (USD Million)
  • Figure 11.38. CRISPR-based Genome Editing Services Market for Other Cell Lines in Rest of the World, 2019-2030 (USD Million)
  • Figure 12.1. CRISPR-based Genome Editing: SWOT Factors
  • Figure 12.2. Comparison of SWOT Factors: Harvey Ball Analysis

List of Tables

  • Table 3.1. Classification of CRISPR-Cas Systems
  • Table 4.1. List of CRISPR-based Genome Editing Service Providers: Information on Type of Service
  • Table 4.2. List of CRISPR-based Genome Editing Service Providers: Information on gRNA Format, Type of Endonuclease and Cas9 Endonuclease Format
  • Table 4.3. List of CRISPR-based Genome Editing Service Providers: Information on Cell Line Engineering Offerings, Animal Model Generation Offerings and Availability of CRISPR Libraries
  • Table 5.1. Company Competitive Analysis: Small-sized Players
  • Table 5.2. Company Competitive Analysis: Mid-sized Players
  • Table 5.3. Company Competitive Analysis: Large Players
  • Table 6.1. CRISPR-based Genome Editing Services Providers: List of Companies Profiled
  • Table 6.2. Applied StemCell: Company Overview
  • Table 6.3. Applied StemCell: CRISPR-based Genome Editing Services
  • Table 6.4. Applied StemCell: Recent Developments and Future Outlook
  • Table 6.5. BioCat: Company Overview
  • Table 6.6. BioCat: CRISPR-based Genome Editing Services
  • Table 6.7. BioCat: Recent Developments and Future Outlook
  • Table 6.8. Charles River Laboratories: Company Overview
  • Table 6.9. Charles River Laboratories: CRISPR-based Genome Editing Services
  • Table 6.10. Charles River Laboratories: Recent Developments and Future Outlook
  • Table 6.11. Cobo Scientific: Company Overview
  • Table 6.12. Cobo Scientific: CRISPR-based Genome Editing Services
  • Table 6.13. Cobo Scientific: Recent Developments and Future Outlook
  • Table 6.14. Creative Biogene: Company Overview
  • Table 6.15. Creative Biogene: CRISPR-based Genome Editing Services
  • Table 6.16. Creative Biogene: Recent Developments and Future Outlook
  • Table 6.17. Cyagen Biosciences: Company Overview
  • Table 6.18. Cyagen Biosciences: CRISPR-based Genome Editing Services
  • Table 6.19. Cyagen Biosciences: Recent Developments and Future Outlook
  • Table 6.20. GeneCopoeia: Company Overview
  • Table 6.21. GeneCopoeia: CRISPR-based Genome Editing Services
  • Table 6.22. GeneCopoeia: Recent Developments and Future Outlook
  • Table 6.23. Horizon Discovery: Company Overview
  • Table 6.24. Horizon Discovery: CRISPR-based Genome Editing Services
  • Table 6.25. Horizon Discovery: Recent Developments and Future Outlook
  • Table 6.26. NemaMetrix: Company Overview
  • Table 6.27. NemaMetrix: CRISPR-based Genome Editing Services
  • Table 6.28. NemaMetrix: Recent Developments and Future Outlook
  • Table 6.29. Synbio Technologies: Company Overview
  • Table 6.30. Synbio Technologies: CRISPR-based Genome Editing Services
  • Table 6.31. Synbio Technologies: Recent Developments and Future Outlook
  • Table 6.32. Thermo Fisher Scientific: Company Overview
  • Table 6.33. Thermo Fisher Scientific: CRISPR-based Genome Editing Services
  • Table 6.34. Thermo Fisher Scientific: Recent Developments and Future Outlook
  • Table 8.1. Grant Analysis: List of Most Attractive Grants
  • Table 9.1. List of CRISPR-based Technology Providers
  • Table 9.2. List of CRISPR-based Technology Providers: Information on Technology
  • Table 9.3. Beam Therapeutics: Funding Instances
  • Table 9.4. Beam Therapeutics: Collaborations
  • Table 9.5. CRISPR Therapeutics: Funding Instances
  • Table 9.6. CRISPR Therapeutics: Collaborations
  • Table 9.7. Editas Medicine: Funding Instances
  • Table 9.8. Editas Medicine: Collaborations
  • Table 9.9. KSQ Therapeutics: Funding Instances
  • Table 9.10. Locus Biosciences: Funding Instances
  • Table 9.11. Locus Biosciences: Collaborations
  • Table 9.12. Refuge Biotechnologies: Funding Instances
  • Table 9.13. Refuge Biotechnologies: Collaborations
  • Table 9.14. Repare Therapeutics: Funding Instances
  • Table 9.15. SNIPR BIOME: Funding Instances
  • Table 9.16. Intellia Therapeutics: Funding Instances
  • Table 9.17. Intellia Therapeutics: Collaborations
  • Table 9.18. List of CRISPR Kit Providers
  • Table 9.19. List of CRISPR Design Tool Providers
  • Table 10.1. Industry Players: Most Likely Partners
  • Table 10.2. Industry Players: Likely Partners
  • Table 10.3. Industry Players: Less Likely Partners
  • Table 10.4. Non-Industry Players: Most Likely Partners
  • Table 10.5. Non-Industry Players: Likely Partners
  • Table 10.6. Non-Industry Players: Less Likely Partners
  • Table 14.1. CRISPR-based Genome Editing Services: Distribution by Type of Service Offering
  • Table 14.2. CRISPR-based Genome Editing Services: Distribution by Type of gRNA Format
  • Table 14.3. CRISPR-based Genome Editing Services: Distribution by Type of Endonuclease
  • Table 14.4. CRISPR-based Genome Editing Services: Distribution by Type of Cas9 Endonuclease Format
  • Table 14.5. CRISPR-based Genome Editing Services: Distribution by Type of Cell Line Engineering
  • Table 14.6. CRISPR-based Genome Editing Services: Distribution by Type of Animal Model Generation
  • Table 14.7. CRISPR-based Genome Editing Services: Distribution by Availability of CRISPR Libraries
  • Table 14.8. CRISPR-based Genome Editing Service Providers: Distribution by Year of Establishment
  • Table 14.9. CRISPR-based Genome Editing Service Providers: Distribution by Company Size
  • Table 14.10. CRISPR-based Genome Editing Service Providers: Distribution by Geographical Location
  • Table 14.11. CRISPR-based Genome Editing Service Providers Logo Landscape: Distribution by Company Size and Location of Headquarters
  • Table 14.12. Charles River Laboratories: Annual Revenues, 2014-H1 2019 (USD Billion)
  • Table 14.13. Horizon Discovery: Annual Revenues, 2014-H1 2019 (EUR Million)
  • Table 14.14. Thermo Fisher Scientific: Annual Revenues, 2014-H1 2019 (USD Million)
  • Table 14.15. Patent Portfolio: Distribution by Type of Patent
  • Table 14.16. Patent Portfolio: Distribution by Application Year
  • Table 14.17. Patent Portfolio: Distribution by Publication Year
  • Table 14.18. Patent Portfolio: Distribution by Geography
  • Table 14.19. Leading Industry Players: Distribution by Size of Patent Portfolio
  • Table 14.20. Leading Non-Industry Players: Distribution by Size of Patent Portfolio
  • Table 14.21. Patent Portfolio: Valuation Analysis
  • Table 14.22. Academic Grant Analysis: Year-wise Trend of Award
  • Table 14.23. Academic Grant Analysis: Distribution by Amount Awarded
  • Table 14.24. Academic Grant Analysis: Distribution by Administering Institutes
  • Table 14.25. Academic Grant Analysis: Distribution by Support Period
  • Table 14.26. Academic Grant Analysis: Distribution by Funding Mechanism
  • Table 14.27. Academic Grant Analysis: Distribution by Type of Grant Application
  • Table 14.28. Academic Grant Analysis: Distribution by Grant Activity
  • Table 14.29. Academic Grant Analysis: Distribution by Recipient Organization
  • Table 14.30. Prominent Project Leaders: Distribution by Number of Grants Awarded
  • Table 14.31. Academic Grant Analysis: Grant Attractiveness Analysis
  • Table 14.32. CRISPR-based Technology Providers: Distribution by Year of Establishment
  • Table 14.33. CRISPR-based Technology Providers: Distribution by Company Size
  • Table 14.34. CRISPR-based Technology Providers: Distribution by Focus Area
  • Table 14.35. Key CRISPR-based Technology Providers: Venture Capital Investments (USD Million)
  • Table 14.36. Overall CRISPR-based Genome Editing Services Market, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.37. CRISPR-based Genome Editing Services Market: Distribution by Regions, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.38. CRISPR-based Genome Editing Services Market in North America, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.39. CRISPR-based Genome Editing Services Market in Europe, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.40. CRISPR-based Genome Editing Services Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.41. CRISPR-based Genome Editing Services Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.42. CRISPR-based Genome Editing Services Market: Distribution by Type of Services, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.43. CRISPR-based Genome Editing Services Market for gRNA Construction, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.44. CRISPR-based Genome Editing Services Market for gRNA Construction in North America, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.45. CRISPR-based Genome Editing Services Market for gRNA Construction in Europe, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.46. CRISPR-based Genome Editing Services Market for gRNA Construction in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.47. CRISPR-based Genome Editing Services Market for gRNA Construction in Rest of the World, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.48. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.49. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.50. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.51. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.52. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.53. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.54. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.55. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.56. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.57. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.58. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.59. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.60. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.61. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.62. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.63. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.64. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.65. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.66. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.67. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.68. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.69. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.70. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.71. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.72. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 14.73. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)

List of Companies

  • 1. 302 Military Hospital of China
  • 2. 4D Molecular Therapeutics
  • 3. AAVogen
  • 4. AB SCIEX
  • 5. AbbVie
  • 6. AbCheck
  • 7. AbClon
  • 8. Abeona Therapeutics
  • 9. ACROBiosystems
  • 10. Actus Therapeutics
  • 11. Acucela
  • 12. Adaptimmune Therapeutics
  • 13. Adicet Bio
  • 14. Advantagene
  • 15. Advaxis
  • 16. Adverum Biotechnologies
  • 17. Adverum Biotechnologies
  • 18. Aeon Therapeutics
  • 19. Affiliated Hospital to Academy of Military Medical Sciences
  • 20. Agency for Science, Technology and Research (A*STAR)
  • 21. AgenTus Therapeutics
  • 22. Agilent Technologies
  • 23. Agilis Biotherapeutics
  • 24. Akouos
  • 25. Albert Einstein College of Medicine
  • 26. Aldevron
  • 27. Alex's Lemonade Stand Foundation
  • 28. Allergan
  • 29. Allife Medical Science and Technology
  • 30. Allogene Therapeutics
  • 31. AlphaVax
  • 32. ALSTEM
  • 33. Altor Bioscience
  • 34. American Gene Technologies
  • 35. Amgen
  • 36. Amicus Therapeutics
  • 37. AMS Biotechnology
  • 38. Anaeropharma Science
  • 39. Analytical Biological Services
  • 40. Anchiano Therapeutics
  • 41. AnGes
  • 42. Angionetics
  • 43. Anhui Provincial Hospital
  • 44. Animalab
  • 45. Antagene
  • 46. Antibody Design Labs
  • 47. Apic Bio
  • 48. Applied Biological Materials (abm)
  • 49. Applied Genetic Technologies (AGTC)
  • 50. Applied StemCell
  • 51. APSIS Therapeutics
  • 52. ARBELE
  • 53. Arbor Biosciences
  • 54. Arthrogen
  • 55. Aruvant Sciences
  • 56. AskBio
  • 57. Astellas Pharma
  • 58. Atara Biotherapeutics
  • 59. Atossa Genetics
  • 60. Atreca
  • 61. ATUM
  • 62. Auburn University
  • 63. Audentes Therapeutics
  • 64. AuraGen
  • 65. Aurora Biopharma
  • 66. Autolus
  • 67. Avacta
  • 68. Avectas
  • 69. AveXis
  • 70. AVROBIO
  • 71. Axol Bioscience
  • 72. Axovant Gene Therapies
  • 73. Bamboo Therapeutics
  • 74. Baxter
  • 75. Bayer
  • 76. Baylor College of Medicine
  • 77. Beam Therapeutics
  • 78. Beijing Biohealthcare Biotechnology
  • 79. Beijing Cancer Hospital
  • 80. Beijing Doing Biomedical
  • 81. Beijing Immunochina Medical Science & Technology
  • 82. Beijing Lu Daopei Hospital
  • 83. Beijing Mario Biotech
  • 84. Beijing Sanbo Brain Hospital
  • 85. Beijing Sanwater Biological Technology
  • 86. Bellicum Pharmaceuticals
  • 87. Benchling
  • 88. Berlin Institute of Health
  • 89. Bill & Melinda Gates Foundation
  • 90. BioAtla
  • 91. BioCat
  • 92. Bioceltech Therapeutics
  • 93. BioChain
  • 94. Biocodon Technologies
  • 95. Biocytogen
  • 96. Biogen
  • 97. BioInvent
  • 98. Biolegio
  • 99. Biologics International
  • 100. BioMarin
  • 101. Bioneer
  • 102. Bionic Sight
  • 103. BioNTech
  • 104. Biotools
  • 105. Bioverativ
  • 106. Blue Heron Biotech
  • 107. bluebird bio
  • 108. B-MoGen Biotechnologies
  • 109. Boehringer Ingelheim
  • 110. Boston Children's Hospital
  • 111. Bristol-Myers Squibb
  • 112. Broad Institute
  • 113. Brown University
  • 114. Butterfly sciences
  • 115. California Institute for Regenerative Medicine
  • 116. California Institute of Technology
  • 117. Calimmune
  • 118. Cambridge Bioscience
  • 119. Cancer Research UK
  • 120. Canopy BioSciences
  • 121. Captain T Cell
  • 122. Cardiogen Sciences
  • 123. Caribou Biosciences
  • 124. Carina Biotech
  • 125. CARsgen Therapeutics
  • 126. Cartesian Therapeutics
  • 127. Cartherics
  • 128. Case Comprehensive Cancer Center
  • 129. CASPR Biotech
  • 130. Castle Creek Pharma
  • 131. Celenex
  • 132. Celgene
  • 133. Cell and Gene Therapy Catapult
  • 134. Cell Medica
  • 135. Cellecta
  • 136. Cellectis
  • 137. CellGenTech
  • 138. CellSystems
  • 139. Cellular Biomedicine Group
  • 140. Cellular Therapeutics
  • 141. Celsion
  • 142. Celvab
  • 143. Celyad
  • 144. Center for Applied Medical Research (CIMA)
  • 145. Center for Cell and Gene Therapy
  • 146. Changhai Hospital
  • 147. Changzheng Hospital
  • 148. Charles River Laboratories
  • 149. Chatham Therapeutics
  • 150. Chiba University
  • 151. Children's Hospital and Health System Foundation
  • 152. Children's Hospital of Fudan University
  • 153. Children's Hospital of Philadelphia
  • 154. Children's Mercy Kansas City
  • 155. China Immunotech
  • 156. China Meitan General Hospital
  • 157. Chinese Academy of Sciences
  • 158. Chinese PLA General Hospital
  • 159. City of Hope National Medical Center
  • 160. Cobo Scientific
  • 161. Coderegenesis
  • 162. Cold Genesys
  • 163. CombiGene
  • 164. Copernicus Therapeutics
  • 165. Cosmo Bio
  • 166. Creative Bioarray
  • 167. Creative Biogene
  • 168. CRISPR Therapeutics
  • 169. CrownBio
  • 170. CSL Behring
  • 171. Cyagen
  • 172. Cynvec
  • 173. Cytovant Sciences
  • 174. Daiichi Sankyo
  • 175. Dana-Farber Cancer Institute
  • 176. Defense Advanced Research Projects Agency (DARPA)
  • 177. DefiniGEN
  • 178. Desktop Genetics
  • 179. Dimension Therapeutics
  • 180. Discovery Genomics
  • 181. DNAlite Therapeutics
  • 182. DNAtrix
  • 183. Dongguan People's Hospital
  • 184. Dow AgroSciences
  • 185. Duke University Medical Center
  • 186. Duke-NUS Medical School
  • 187. EdiGene
  • 188. Editas Medicine
  • 189. eGenesis Bio
  • 190. Ehime University
  • 191. Eli Lilly
  • 192. Endocyte
  • 193. Endsulin
  • 194. Enochian BioSciences
  • 195. Entos Pharmaceuticals
  • 196. Epeius Biotechnologies
  • 197. Errant Gene Therapeutics
  • 198. ERS Genomics
  • 199. Esteve
  • 200. Eureka Therapeutics
  • 201. Eutilex
  • 202. Exonics Therapeutics
  • 203. ExpressCells
  • 204. Expression Therapeutics
  • 205. EXUMA Biotechnology
  • 206. Eyevensys
  • 207. F1 Oncology
  • 208. Fate Therapeutics
  • 209. Federal Research and Clinical Centre of Pediatric Hematology, Oncology and Immunology
  • 210. Fibrocell
  • 211. First Affiliated Hospital of Chengdu Medical College
  • 212. First Affiliated Hospital of Guangdong Pharmaceutical University
  • 213. First Affiliated Hospital of Zhejiang University
  • 214. First People's Hospital of Foshan
  • 215. First People's Hospital of Yunnan
  • 216. FIT Biotech
  • 217. Five Prime Therapeutics
  • 218. FKD Therapies
  • 219. Flexion Therapeutics
  • 220. Fondazione Matilde Tettamanti Menotti De Marchi Onlus
  • 221. Forevertek Biotechnology
  • 222. Formula Pharmaceuticals
  • 223. Fosun Pharma
  • 224. Fred Hutchinson Cancer Research Center
  • 225. Freeline Therapeutics
  • 226. Fuda Cancer Hospital
  • 227. Fudan University
  • 228. Fujian Cancer Hospital
  • 229. Fujian Medical University
  • 230. Fujita Health University
  • 231. Fulcrum Therapeutics
  • 232. Gadeta
  • 233. GEG Tech
  • 234. Gemini Therapeutics
  • 235. Genable Technologies
  • 236. GenAhead Bio
  • 237. GeneCopoeia
  • 238. GeneCure Biotechnologies
  • 239. GenEdit
  • 240. Genelux
  • 241. Genentech
  • 242. GeneOne Life Science
  • 243. GenePharma
  • 244. GeneQuine Biotherapeutics
  • 245. Generation Bio
  • 246. Genethon
  • 247. Genetics Research
  • 248. GENEWIZ
  • 249. Genexine
  • 250. Genmab
  • 251. genOway
  • 252. Genprex
  • 253. GenScript
  • 254. GenSight Biologics
  • 255. Genus Oncology
  • 256. GenVec
  • 257. German Cancer Research Center
  • 258. GigaGen
  • 259. GlaxoSmithKline
  • 260. Glycostem
  • 261. Gracell Biotechnologies
  • 262. Gradalis
  • 263. Green Cross Cell
  • 264. GSK
  • 265. Guangdong General Hospital
  • 266. Guangdong Xiangxue Precision Medical Technology
  • 267. Guangdong Zhaotai InVivo Biomedicine
  • 268. Guangzhou Anjie Biomedical Technology
  • 269. Guangzhou Doublle Bioproducts
  • 270. Guangzhou Eighth People's Hospital
  • 271. Guangzhou FineImmune Biotechnology
  • 272. Guangzhou First People's Hospital
  • 273. Guangzhou Yi Yan Biological Technology
  • 274. Gynecologic Oncology Group Foundation
  • 275. Gyroscope Therapeutics
  • 276. Hanyang University
  • 277. Harvard College
  • 278. Harvard University
  • 279. Hebei Senlang Biotechnology
  • 280. Hebei Yanda Ludaopei Hospital
  • 281. Hefei Binhu Hospital
  • 282. Heidelberg University
  • 283. Helix BioPharma
  • 284. Helixmith
  • 285. Hemera Biosciences
  • 286. Henan Cancer Hospital
  • 287. Henan Hualong Biotechnology
  • 288. Herantis Pharma
  • 289. Histogenics
  • 290. Holostem Terapie Avanzate
  • 291. Homology Medicines
  • 292. HORAMA
  • 293. Horizon Discovery
  • 294. Hrain Biotechnology
  • 295. Huaian First People's Hospital
  • 296. Huazhong Agricultural University
  • 297. Huazhong University of Science and Technology
  • 298. Human Stem Cells Institute
  • 299. Hunan Provincial People's Hospital
  • 300. Hunan Yongren Medical Innovation
  • 301. Hunan Zhaotai Yongren Biotech
  • 302. Hunterian Medicine
  • 303. Icahn School of Medicine at Mount Sinai
  • 304. iCAR Bio Therapeutics
  • 305. iCarTAB BioMed
  • 306. iCell Gene Therapeutics
  • 307. Icell Kealex Therapeutics
  • 308. ICON
  • 309. IDeal Genetics
  • 310. i-DNA Biotechnology
  • 311. ILPEN Scientific Equipment & Supplies
  • 312. Immatics
  • 313. Immune Therapeutics
  • 314. Immunocore
  • 315. ImmunoGenes
  • 316. Immusoft
  • 317. ingenious targeting laboratory
  • 318. Innovative Cellular Therapeutics
  • 319. Inotek Pharmaceuticals
  • 320. Inovio Pharmaceuticals
  • 321. Inscripta
  • 322. Institute of Hematology & Blood Diseases Hospital
  • 323. Integrated DNA Technologies
  • 324. Intellia Therapeutics
  • 325. Intrexon
  • 326. Invectys
  • 327. Iowa State University
  • 328. IVERIC bio
  • 329. IWK Health Centre is affiliated to Dalhousie University, to be added as separate entries
  • 330. Janssen Pharmaceuticals
  • 331. Jennerex Biotherapeutics
  • 332. Jenthera Therapeutics
  • 333. Jichi Medical University
  • 334. Jingzhou Central Hospital
  • 335. Johns Hopkins Kimmel Cancer Center
  • 336. Jonsson Comprehensive Cancer Center
  • 337. Juno Therapeutics
  • 338. Juventas Therapeutics
  • 339. JW Biotechnology
  • 340. KAEDI
  • 341. King's College London
  • 342. Kite Pharma
  • 343. Kolon TissueGene
  • 344. Krystal Biotech
  • 345. KSQ Therapeutics
  • 346. Labomics
  • 347. Lacerta Therapeutics
  • 348. Leiden University Medical Center
  • 349. Leland Stanford Junior University
  • 350. Leucid Bio
  • 351. LifeEDIT
  • 352. Ligandal
  • 353. Liminatus Pharma
  • 354. Lion TCR
  • 355. Living Pharma
  • 356. Locus Biosciences
  • 357. LogicBio Therapeutics
  • 358. Lokon Pharma
  • 359. Lonza
  • 360. Loop Genomics
  • 361. Loyola University
  • 362. LubioScience
  • 363. Lucigen
  • 364. Ludwig Cancer Research
  • 365. Lysogene
  • 366. MabVax Therapeutics
  • 367. Macrogen
  • 368. Mammoth Biosciences
  • 369. Marino Biotechnology
  • 370. Marsala Biotech
  • 371. Massachusetts General Hospital
  • 372. Massachusetts Institute of Technology
  • 373. MaxCyte
  • 374. Mayo Clinic
  • 375. MD Anderson Cancer Center
  • 376. Medical College of Wisconsin
  • 377. Medigene
  • 378. MedImmune
  • 379. Medisix Therapeutics
  • 380. MeiraGTx
  • 381. Memorial Sloan Kettering Cancer Center
  • 382. Merck
  • 383. Mesoblast
  • 384. Microsynth
  • 385. Mie University Hospital
  • 386. Milo Biotechnology
  • 387. Miltenyi Biotec
  • 388. Minerva Biotechnologies
  • 389. MingJu Therapeutics
  • 390. Mirimus
  • 391. Moffitt Cancer Center
  • 392. MolMed
  • 393. Momotaro-Gene
  • 394. Monsanto
  • 395. MultiVir
  • 396. Mustang Bio
  • 397. Myonexus Therapeutics
  • 398. Nagoya University
  • 399. Nanfang Hospital of Southern Medical University
  • 400. Nanjing Children's Hospital
  • 401. Nanjing Legend Biotech
  • 402. NanoCor Therapeutics
  • 403. Nanogenics
  • 404. Nanosens Innovations
  • 405. National Cancer Institute
  • 406. National Eye Institute
  • 407. National Heart, Lung, and Blood Institute
  • 408. National Human Genome Research Institute
  • 409. National Institute of Aging
  • 410. National Institute of Allergy and Infectious Diseases
  • 411. National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • 412. National Institute of Child Health and Human Development
  • 413. National Institute of Diabetes and Digestive and Kidney Diseases
  • 414. National Institute of General Medical Sciences
  • 415. National Institute of Mental Health
  • 416. National Institute of Neurological Disorders and Stroke
  • 417. National Institute on Drug Abuse
  • 418. National Institutes of Health
  • 419. Nationwide Children's Hospital
  • 420. Navy General Hospital
  • 421. Ncardia
  • 422. NemaMetrix
  • 423. Neuracle Genetics
  • 424. Neuralgene
  • 425. Neurocrine Biosciences
  • 426. Neurogene
  • 427. New England Biolabs
  • 428. Nightstar Therapeutics
  • 429. Ningbo Cancer Hospital
  • 430. NIPRO
  • 431. NMI TT Pharmaservices
  • 432. Noahgen
  • 433. Nohla Therapeutics
  • 434. Noile-Immune Biotech
  • 435. Novartis
  • 436. NTrans Technologies
  • 437. Obsidian Therapeutics
  • 438. Ocugen
  • 439. omicX
  • 440. Oncolys BioPharma
  • 441. Oncos Therapeutics
  • 442. OncoSec Medical
  • 443. Orbit Biomedical
  • 444. ORCA Therapeutics
  • 445. Orchard Therapeutics
  • 446. OriGene Technologies
  • 447. Ottawa Hospital Research Institute
  • 448. Oxford BioMedica
  • 449. Oxford Genetics
  • 450. OZ Biosciences
  • 451. Pacific Biosciences
  • 452. Parker Institute for Cancer Immunotherapy
  • 453. Passage Bio
  • 454. Pattern BioSciences
  • 455. Peking University
  • 456. PeproMene Bio
  • 457. PeriphaGen
  • 458. PersonGen BioTherapeutics
  • 459. Peter MacCallum Cancer Centre
  • 460. Pfizer
  • 461. PHENOMIN-ICS
  • 462. Pinze Lifetechnology
  • 463. Pioneer Hi-Bred International
  • 464. PlasmaTech Biopharmaceuticals
  • 465. PNA Bio
  • 466. PolyGene
  • 467. Poseida Therapeutics
  • 468. Precigen
  • 469. Precision BioSciences
  • 470. Precision Genome Engineering
  • 471. Precision Virologics
  • 472. Prevail Therapeutics
  • 473. Promab Biotechnologies
  • 474. Promega
  • 475. Promethera Biosciences
  • 476. Protheragen
  • 477. PsiOxus Therapeutics
  • 478. PTC Therapeutics
  • 479. Purdue University
  • 480. Qingdao Central Hospital
  • 481. Quethera
  • 482. Recombinetics
  • 483. Refuge Biotechnologies
  • 484. Regeneron Pharmaceuticals
  • 485. REGENXBIO
  • 486. RenJi Hospital
  • 487. Renova Therapeutics
  • 488. Rentschler Biopharma
  • 489. Repare Therapeutics
  • 490. ReproCELL
  • 491. RetroSense Therapeutics
  • 492. Reyon Pharmaceutical
  • 493. Roche
  • 494. Rocket Pharmaceuticals
  • 495. Rockland Immunochemicals
  • 496. Roger Williams Medical Center
  • 497. Roswell Park Cancer Institute
  • 498. Royal Adelaide Hospital Cancer Centre
  • 499. Ruijin Hospital
  • 500. Ryboquin
  • 501. San Raffaele Hospital
  • 502. Sanct
  • 503. Sangamo Therapeutics
  • 504. Sanofi
  • 505. Sarepta Therapeutics
  • 506. SCANBUR
  • 507. Scancell
  • 508. SciGenom Labs
  • 509. Scotia Biologics
  • 510. Seattle Children's Hospital
  • 511. Seattle Children's Research Institute
  • 512. Seattle Genetics
  • 513. Second Affiliated Hospital of Guangzhou Medical University
  • 514. Second Affiliated Hospital of Xi'an Jiaotong University
  • 515. Second Military Medical University
  • 516. Second Xiangya Hospital of Central South University
  • 517. Selecta Biosciences
  • 518. Servier
  • 519. Shanghai Bioray Laboratory
  • 520. Shanghai Changzheng Hospital
  • 521. Shanghai Children's Medical Center
  • 522. Shanghai East Hospital
  • 523. Shanghai GeneChem
  • 524. Shanghai General Hospital
  • 525. Shanghai International Medical Center
  • 526. Shanghai Jiao Tong University School of Medicine
  • 527. Shanghai Longyao Biotechnology
  • 528. Shanghai Public Health Clinical Center
  • 529. Shanghai Sinobioway Sunterra Biotech
  • 530. Shanghai Sixth People's Hospital
  • 531. Shanghai Sunway Biotech
  • 532. Shanghai Tenth People's Hospital
  • 533. Shanghai Tong Ren Hospital
  • 534. Shanghai Tongji Hospital
  • 535. Shanghai Unicar-Therapy Bio-medicine Technology
  • 536. Sheba Medical Center
  • 537. Shenzhen BinDeBio
  • 538. Shenzhen Geno-immune Medical Institute
  • 539. Shenzhen Institute for Innovation and Translational Medicine
  • 540. Shenzhen Second People's Hospital
  • 541. Sherlock Biosciences
  • 542. Shionogi
  • 543. Shire (acquired by Takeda Pharmaceutical)
  • 544. Sibiono GeneTech
  • 545. Sichuan University
  • 546. Sidney Kimmel Cancer Center
  • 547. Sigma Aldrich
  • 548. SillaJen
  • 549. Sinobioway Cell Therapy
  • 550. SNIPR BIOME
  • 551. Solid Biosciences
  • 552. Sorrento Therapeutics
  • 553. Southern Medical University
  • 554. Southwest Hospital
  • 555. Spanish National Centre for Biotechnology
  • 556. Spark Therapeutics
  • 557. Spindle Biotech
  • 558. SR-TIGET
  • 559. St. Jude Children's Research Hospital
  • 560. Stanford University
  • 561. STEMCELL Technologies
  • 562. Stony Brook University
  • 563. StrideBio
  • 564. Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
  • 565. SunyBiotech
  • 566. Super-T Cell Cancer Company
  • 567. Syd Labs
  • 568. Symvivo
  • 569. Synbio Technologies
  • 570. Syngenta Participations
  • 571. Synthego
  • 572. System Biosciences
  • 573. Taconic Biosciences
  • 574. Tactiva Therapeutics
  • 575. Takara Bio
  • 576. Takeda Pharmaceutical
  • 577. Targazyme
  • 578. Targovax
  • 579. Tasly Biopharmaceuticals
  • 580. Taxus Cardium Pharmaceuticals
  • 581. TC BioPharm
  • 582. TCR2 Therapeutics
  • 583. TCRCure Biopharma
  • 584. tebu-bio
  • 585. Tenaya Therapeutics
  • 586. Tessa Therapeutics
  • 587. Texas Children's Hospital
  • 588. The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
  • 589. The Bambino Gesu` Children's Hospital
  • 590. The Beijing Pregene Science and Technology
  • 591. The Cancer Hospital of Yunnan
  • 592. The First Affiliated Hospital of Anhui Medical University
  • 593. The First Affiliated Hospital of Chongqing Medical University
  • 594. The First Affiliated Hospital of Harbin Medical University
  • 595. The First Affiliated Hospital of Jinan University
  • 596. The First Affiliated Hospital of Soochow University
  • 597. The First Affiliated Hospital of Wenzhou Medical University
  • 598. The First Affiliated Hospital of Zhengzhou University
  • 599. The First Affiliated Hospital with Nanjing Medical University
  • 600. The First Hospital of Jilin University
  • 601. The First People's Hospital of Hefei
  • 602. The First People's Hospital of Yuhang District
  • 603. The General Hospital of Western Theater Command
  • 604. The Methodist Hospital System
  • 605. The Netherlands Cancer Institute
  • 606. The Pregene (ShenZhen) Biotechnology
  • 607. The Second Affiliated Hospital of Hainan Medical University
  • 608. The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
  • 609. The Second Hospital of Anhui Medical University
  • 610. The Second Hospital of Hebei Medical University
  • 611. The Second Hospital of Nanjing Medical University
  • 612. The Second Military Medical University
  • 613. The Sixth Affiliated Hospital of Wenzhou Medical University
  • 614. The Third Affiliated Hospital of Southern Medical University
  • 615. The University of Chicago
  • 616. The Wistar Institute
  • 617. TheraBiologics
  • 618. THERAVECTYS
  • 619. Thermo Fisher Scientific
  • 620. Third Affiliated Hospital
  • 621. Third Military Medical University
  • 622. Thomas Jefferson University
  • 623. THP Medical Products
  • 624. Tianjin Medical University Cancer Institute and Hospital
  • 625. Tianjin Mycure Medical Technology
  • 626. Tianjin People's Hospital
  • 627. TILT Therapeutics
  • 628. Timmune Biotech
  • 629. Tmunity Therapeutics
  • 630. TNK Therapeutics, subsidiary of Sorrento Therapeutics
  • 631. Tocagen
  • 632. Tongji Hospital
  • 633. Tongji Medical College
  • 634. Tongji University School of Medicine
  • 635. Toni Stephenson Lymphoma Center
  • 636. ToolGen
  • 637. Transgene
  • 638. Transposagen Biopharmaceuticals
  • 639. Trilink Biotechnologies
  • 640. TxCell
  • 641. UC Davis Medical Center
  • 642. UK Cystic Fibrosis Gene Therapy Consortium
  • 643. Ultragenyx Pharmaceutical
  • 644. UNC Lineberger Comprehensive Cancer Center
  • 645. Union Stem Cell & Gene Engineering
  • 646. uniQure Biopharma
  • 647. United States Department of Defense
  • 648. Universal Cells
  • 649. Universitat Autònoma de Barcelona
  • 650. University Health Network
  • 651. University Hospital Heidelberg
  • 652. University Medical Center Utrecht
  • 653. University of Bergen
  • 654. University of California
  • 655. University of Cologne
  • 656. University of Connecticut
  • 657. University of Florida
  • 658. University of Georgia
  • 659. University of Massachusetts Medical School
  • 660. University of Oxford
  • 661. University of Pennsylvania
  • 662. University of Southern California
  • 663. University of Technology
  • 664. University of Texas MD Anderson Cancer Center
  • 665. University of Zurich
  • 666. Unum Therapeutics
  • 667. Uppsala University
  • 668. Urovant Sciences
  • 669. UT Southwestern Medical Center
  • 670. V Foundation
  • 671. ValueAct Capital Management
  • 672. VBL Therapeutics
  • 673. VCN Biosciences
  • 674. Vector Neurosciences
  • 675. VectorBuilder
  • 676. Velaz
  • 677. Vertex Pharmaceuticals
  • 678. Verve Therapeutics
  • 679. Vessl™
  • 680. Vigene Biosciences
  • 681. Virttu Biologics
  • 682. Vivet Therapeutics
  • 683. Vivo Bio Tech
  • 684. Vor Biopharma
  • 685. Voyager Therapeutics
  • 686. Washington University
  • 687. Weill Cornell Medical College
  • 688. Welgen
  • 689. West China Hospital
  • 690. Wuhan Sian Medical Technology
  • 691. Wuhan Union Hospital
  • 692. WuXi AppTec
  • 693. Wyvern Pharmaceuticals
  • 694. Xiangxue Life Sciences
  • 695. Xiangxue Pharmaceutical
  • 696. Xiangyang Central Hospital
  • 697. Xijing Hospital
  • 698. Xinqiao Hospital
  • 699. XpressBio
  • 700. Xuanwu Hospital
  • 701. Xuzhou Medical University
  • 702. XyloCor Therapeutics
  • 703. Yake Biotechnology
  • 704. Yale University
  • 705. Yamaguchi University Graduate School of Medicine
  • 706. Yan'an Affiliated Hospital of Kunming Medical University
  • 707. Yuanyi Biotechnology
  • 708. ZeClinics
  • 709. Zelluna Immunotherapy
  • 710. ZenBio
  • 711. Zhejiang University
  • 712. Zhongshan Hospital
  • 713. Zhujiang Hospital of Southern Medical University
  • 714. Ziopharm Oncology
目次

Example Insights:

Since the introduction of CRISPR, several players across the world have undertaken initiatives, funded by private and public investments, to further improve / modify the technology to be used for a diverse range of applications.

Overview:

The 1970s witnessed the introduction of one of the most revolutionary advances in biotechnology, when Hamilton Smith (a molecular biologist at Johns Hopkins University School of Medicine) purified the first site-specific restriction enzyme, called Hind II. This development enabled the scientific community to devise the means to manipulate living organisms at the genetic level, opening up a plethora of opportunities in fundamental and applied life science research. Soon after, in the 1980s, the US FDA approved the world's first genetically engineered drug, which was human insulin marketed under the brand name HUMULIN®. Genetic engineering and genome editing concepts have evolved significantly over the last two decades, with the development of a variety of versatile DNA modulation technologies including zinc finger nucleases, transcription activator-like effector-based nucleases (TALENs), and the clustered regularly interspaced short palindromic repeats (CRISPR). These developments have enabled medical researchers to perform an array of gene / cell line engineering experiments, including gene knockdowns, gene overexpressions and single base editing, for a variety of R&D applications. It is worth highlighting that, of all the available genome manipulation technologies, CRISPR is currently considered to be the most popular tool, owing to its fast, accurate, and cost-effective approach. In fact, in 2018, scientists Emmanuelle Charpentier, Jennifer Doudna, and Virginijus Siksnys were felicitated for their pioneering efforts on the CRISPR-Cas9 technology, with the prestigious Kavli Prize in Nanoscience.

Currently, there is an evident increase in demand for complex biological therapies (including regenerative medicine products), which has created an urgent need for robust genome editing techniques. The biopharmaceutical pipeline includes close to 500 gene therapies, several of which are being developed based on the CRISPR technology. Recently, in July 2019, a first in vivo clinical trial for a CRISPR-based therapy was initiated. However, successful gene manipulation efforts involve complex experimental protocols and advanced molecular biology centered infrastructure. Therefore, many biopharmaceutical researchers and developers have demonstrated a preference to outsource such operations to capable contract service providers. Consequently, the genome editing contract services market was established and has grown to become an indispensable segment of the modern healthcare industry, offering a range of services, such as gRNA design and construction, cell line development (involving gene knockout, gene knockin, tagging and others) and transgenic animal model generation (such as knockout mice). Additionally, there are several players focused on developing advanced technology platforms that are intended to improve / augment existing gene editing tools, especially the CRISPR-based genome editing processes. Given the rising interest in personalized medicine, a number of strategic investors are presently willing to back genetic engineering focused initiatives. Prevalent trends indicate that the market for CRISPR-based genome editing services is likely to grow at a significant pace in the foreseen future.

The “Genome Editing Services Market: Focus on CRISPR, 2019-2030” report features an extensive study of the current landscape of CRISPR-based genome editing service providers. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographical regions. Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape, featuring an elaborate list of over 80 companies that offer CRISPR-based genome editing services, and analyses based on a number of relevant parameters, such as type of gRNA service, availability of gRNA format, type of endonuclease, type of Cas9 endonuclease format, type of cell line engineering offering, type of cell line, type of animal model generation offering, availability of CRISPR libraries and important service provider details (year of establishment, company size and location of headquarters).
  • An insightful 2X2 representation, highlighting the competitiveness of various CRISPR-based genome editing service providers captured in our database (segregated across various peer groups based on company size), taking into consideration the supplier power and the specific genome editing capabilities (which include gRNA service(s), endonuclease service(s), cell line engineering service(s), animal model generation service(s) and availability of CRISPR library(s)) of different companies.
  • Elaborate profiles of key players (shortlisted based on strength of service portfolio), featuring a brief overview of the company, its financial performance (if available), a detailed description of its genome editing service offerings, recent developments and an informed future outlook.
  • An in-depth analysis of over 10,000 patents related to CRISPR technology that have been filed / granted, since 2006, highlighting key trends associated with these patents, across type of patent, publication year and application year, regional applicability, CPC symbols, emerging focus areas, leading patent assignees (in terms of number of patents filed / granted), patent benhcmarking and valuation.
  • A detailed analysis of close to 2,000 grants that have been awarded to support research projects related to CRISPR, between 2015 and 2019 (till September), highlighting important parameters, such as year of award, amount awarded, administring institute center, support period, funding mechanism, type of grant application, grant activity, type of recipient organization, regional distribution of recipient organization, prominent project leaders and emerging focus areas. It also features a detailed multivariate grant attractiveness analysis based on the amount awarded, support period, grant type and funding mechanism.
  • A discussion on the advanced technologies and systems that have been developed to improve CRISPR-related processes. It includes a list of companies that have developed such innovative technology platforms, along with details on a number of relevant parameters, such as year of establishment, company size, core expertise, location of headquarters and important technology specifications (including technology name, focus area and key features). In addition, it includes short profiles of key technology providers. Further, the chapter highlights a list of companies that offer CRISPR kits and CRISPR design tools.
  • An analysis highlighting potential strategic partners, segregated based on likelihood of entering into collaboration with CRISPR-based genome editing services providers. The analysis takes into consideration multiple relevant parameters, such as type of therapy, pipeline strength, pipeline maturity, company strength and therapeutic area.
  • A discussion on important, industry-specific trends, key market drivers and challenges, under a SWOT framework, featuring a qualitative Harvey ball analysis that highlights the relative impact of each SWOT parameter on the overall market.

One of the key objectives of the report was to evaluate the current opportunity and the future potential of CRISPR-based genome editing services market. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2019-2030. In addition, we have segmented the future opportunity across [A] type of services offered (gRNA construction, cell line engineering and animal model generation), [B] type of cell line used (mammalian, microbial, insect and others) and [C] different geographical regions (North America, Europe, Asia Pacific and rest of the world). To account for the uncertainties associated with the CRISPR-based genome editing services market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights generated from both secondary and primary research. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter Outlines:

Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high-level view on the likely evolution of the CRISPR-based genome editing services market in the short to mid-term, and long term.

Chapter 3 provides a brief overview, history and applications of genome editing. It includes detailed discussion on the different types of currently available genome editing techniques. In addition, the chapter provides details of CRISPR technology along with the information on role of CRISPR / Cas in bacterial adaptive immunity, key CRISPR / Cas systems and components of CRISPR / Cas system. Further, it includes details on protocol associated with CRISPR-based genome editing, applications of CRISPR and associated key challenges and future perspectives.

Chapter 4 provides a comprehensive view on the current landscape of CRISPR-based genome editing service providers. It includes information related to over 80 companies that claim to offer CRISPR-based genome editing services, featuring an in-depth analyses of the players based on their service offering including gRNA service (gRNA design and gRNA construction), availability of gRNA format (plasmid, lentivirus, AAV, adenovirus and others), type of endonuclease (Cas9, Cpf1 and others), availability of Cas9 format (mRNA, plasmid, lentivirus, AAV, protein and others), type of cell line engineering offering (knockout, knockin, tagging / reporters and others), type of cell line (stem cell lines, human cell lines, other mammalian cell lines and others (microbial, insects and others)), type of animal model generation offering (mice / mouse, rat, zebrafish, C.elegans and others), availability of CRISPR libraries and important service provider details (year of establishment, headquarter location(s), company size).

Chapter 5 features a comprehensive 2X2 analysis offering a comparative summary of all the CRISPR-based genome editing service providers that we came across during our research. The analysis compares the aforementioned companies within three peer-groups, established based on size of employee base (small-sized (1-200 employees), mid-sized (>201-1,000 employees) and large (>1,000 employees)). The companies were compared based on their genome editing capabilities (including gRNA service(s), endonuclease service(s), cell line service(s), animal model generation service(s), CRISPR library(s)) and supplier power.

Chapter 6 features profiles of CRISPR-based genome editing service providers (shortlisted based on strength of service portfolio). Each profile features an overview of the company, its financial performance (if available), brief details of genome editing service portfolio, recent developments and an informed future outlook.

Chapter 7 provides an in-depth patent analysis to provide an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered those patents that have been filed since 2006 related to CRISPR technology. The analysis also highlights the key trends associated with these patents, including type of patent (granted patent, patent application and others), publication year and application year, geography (North America, Europe, Asia-Pacific and Rest of the World), CPC symbols (Top 15 CPC symbols), key focus areas, leading industry / non-industry players, patent benchmarking analysis and patent valuation analysis.

Chapter 8 provides information on close to 2,200 grants that were awarded to research institutes engaged in projects related to CRISPR technology, between 2015 and 2019 (till September). The analysis also highlights important parameters associated with grants, such as year of award, amount awarded, administering institute center, support period, funding mechanism, type of grant application, grant activity, type of recipient organization, regional distribution of recipient organization, prominent project leaders and emerging focus areas. It also features a detailed multivariate grant attractiveness analysis based on the amount awarded, support period, grant type and funding mechanism.

Chapter 9 provides details of innovative technology platforms (such as integration of delivery platforms, enzyme technologies, protein technologies and others with the fundamental CRISPR technology) to improve CRISPR processes. It includes the list of companies that are focused on the development of these technologies along with details on a number of parameters, such as year of establishment, headquarter location(s), company size, company expertise and technology details (name, focus and key features). In addition, it includes tabulated profiles of key technology providers, with details on company overview, funding and collaboration instances. Further, the chapter highlights a list of companies that offer CRISPR design tools and kits.

Chapter 10 features an insightful analysis, highlighting potential strategic partners (for instance, drug developers) for CRISPR-based genome editing service providers, based on multiple parameters, such as type of therapy, pipeline strength, pipeline maturity, company strength and therapeutic area. The analysis aims to provide the necessary inputs to the stakeholders, enabling them to make the right decisions to conduct research work with the help the appropriate partner entities.

Chapter 11 features a comprehensive market forecast, highlighting the future potential of CRISPR-based genome editing services market till 2030. The projected opportunity has been further analyzed to develop a better perspective related to its distribution across [A] type of services (gRNA construction, cell line engineering and animal model generation), [B] type of cell line (mammalian, microbial, insect and others) and [C] different global regions (North America, Europe, Asia-Pacific and rest of the world).

Chapter 12 provides a discussion on important industry-specific trends, key market drivers and challenges, under a SWOT framework, featuring a qualitative Harvey ball analysis, that highlights the relative impact of each SWOT parameter on the overall CRISPR-based genome editing services market.

Chapter 13 is a collection of transcripts of the interviews conducted with representatives from renowned organizations that are engaged in the CRISPR technology domain.

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures in the report.

Chapter 15 is an appendix that provides the list of companies and organizations that have been mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Context and Background
  • 3.2. Overview of Genome Editing
  • 3.3. History of Genome Editing
  • 3.4. Applications of Genome Editing
  • 3.5. Genome Editing Techniques
    • 3.5.1. Mutagenesis
    • 3.5.2 Conventional Homologous Recombination
    • 3.5.3 Single Stranded Oligo DNA Nucleotides Homologous Recombination
    • 3.5.4. Homing Endonuclease Systems (Adeno Associated Virus System)
    • 3.5.5. Protein-based Nuclease Systems
      • 3.5.5.1. Meganucleases
      • 3.5.5.2. Zinc Finger Nucleases
      • 3.5.5.3. Transcription Activator-like Effector Nucleases
    • 3.5.6. DNA Guided Systems
      • 3.5.6.1. Peptide Nucleic Acids
      • 3.5.6.2. Triplex Forming Oligonucleotides
      • 3.5.6.3. Structure Guided Endonucleases
    • 3.5.7. RNA Guided Systems
      • 3.5.7.1. CRISPR-Cas9
      • 3.5.7.2. Targetrons
  • 3.6. CRISPR-based Genome Editing
    • 3.6.1. Role of CRISPR-Cas in Adaptive Immunity in Bacteria
    • 3.6.2. Key CRISPR-Cas Systems
    • 3.6.3. Components of CRISPR-Cas System
    • 3.6.4. Protocol for CRISPR-based Genome Editing
  • 3.7. Applications of CRISPR
    • 3.7.1. Development of Therapeutic Interventions
    • 3.7.2. Augmentation of Artificial Fertilization Techniques
    • 3.7.3. Development of Genetically Modified Organisms
    • 3.7.4. Production of Biofuels
    • 3.7.5. Other Bioengineering Applications
  • 3.8. Key Challenges and Future Perspectives

4. CRISPR-BASED GENOME EDITING SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. CRISPR-based Genome Editing Service Providers: Overall Market Landscape
    • 4.2.3. Analysis by Type of Service Offering
    • 4.2.4. Analysis by Type of gRNA Format
    • 4.2.5. Analysis by Type of Endonuclease
    • 4.2.6. Analysis by Type of Cas9 Format
    • 4.2.7. Analysis by Type of Cell Line Engineering Offering
    • 4.2.8. Analysis by Type of Animal Model Generation Offering
    • 4.2.9. Analysis by Availability of CRISPR Libraries
    • 4.2.10. Analysis by Year of Establishment
    • 4.2.11. Analysis by Company Size
    • 4.2.12. Analysis by Geographical Location
    • 4.2.13. Logo Landscape: Distribution by Company Size and Location of Headquarters

5. COMPANY COMPETITIVENESS ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Methodology
  • 5.3. Assumptions and Key Parameters
  • 5.4. CRISPR-based Genome Editing Service Providers: Competitive Landscape
    • 5.4.1. Small-sized Companies
    • 5.4.2. Mid-sized Companies
    • 5.4.3. Large Companies

6. COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. Applied StemCell
    • 6.2.1. Company Overview
    • 6.2.2. Service Portfolio
    • 6.2.3. Recent Developments and Future Outlook
  • 6.3. BioCat
    • 6.3.1. Company Overview
    • 6.3.2. Service Portfolio
    • 6.3.3. Recent Developments and Future Outlook
  • 6.4. Biotools
    • 6.4.1. Company Overview
    • 6.4.2. Service Portfolio
    • 6.4.3. Recent Developments and Future Outlook
  • 6.5. Charles River Laboratories
    • 6.5.1. Company Overview
    • 6.5.2. Financial Information
    • 6.5.3. Service Portfolio
    • 6.5.4. Recent Developments and Future Outlook
  • 6.6. Cobo Scientific
    • 6.6.1. Company Overview
    • 6.6.2. Service Portfolio
    • 6.6.3. Recent Developments and Future Outlook
  • 6.7. Creative Biogene
    • 6.7.1. Company Overview
    • 6.7.2. Service Portfolio
    • 6.7.3. Recent Developments and Future Outlook
  • 6.8. Cyagen Biosciences
    • 6.8.1. Company Overview
    • 6.8.2. Service Portfolio
    • 6.8.3. Recent Developments and Future Outlook
  • 6.9. GeneCopoeia
    • 6.9.1. Company Overview
    • 6.9.2. Service Portfolio
    • 6.9.3. Recent Developments and Future Outlook
  • 6.10. Horizon Discovery
    • 6.10.1. Company Overview
    • 6.10.2. Financial Information
    • 6.10.3. Service Portfolio
    • 6.10.4. Recent Developments and Future Outlook
  • 6.11. NemaMetrix
    • 6.11.1. Company Overview
    • 6.11.2. Service Portfolio
    • 6.11.3. Recent Developments and Future Outlook
  • 6.12. Synbio Technologies
    • 6.12.1. Company Overview
    • 6.12.2. Service Portfolio
    • 6.12.3. Recent Developments and Future Outlook
  • 6.13. Thermo Fisher Scientific
    • 6.13.1. Company Overview
    • 6.13.2. Financial Information
    • 6.13.3. Service Portfolio
    • 6.13.4. Recent Developments and Future Outlook

7. PATENT ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Scope and Methodology
  • 7.3. CRISPR-based Genome Editing: Patent Analysis
    • 7.3.1. Analysis by Application Year and Publication Year
    • 7.3.2. Analysis by Geography
    • 7.3.3. Analysis by CPC Symbols
    • 7.3.4. Emerging Focus Areas
    • 7.3.5. Leading Players: Analysis by Number of Patents
  • 7.4. CRISPR-based Genome Editing: Patent Benchmarking Analysis
    • 7.4.1. Analysis by Patent Characteristics
  • 7.5. Patent Valuation Analysis

8. ACADEMIC GRANT ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Scope and Methodology
  • 8.3. Grants Awarded by the National Institutes of Health for CRISPR-based
    • 8.3.1. Year-wise Trend of Grant Award
    • 8.3.2. Analysis by Amount Awarded
    • 8.3.3. Analysis by Administering Institutes
    • 8.3.4. Analysis by Support Period
    • 8.3.5. Analysis by Funding Mechanism
    • 8.3.6. Analysis by Type of Grant Application
    • 8.3.7. Analysis by Grant Activity
    • 8.3.8. Analysis by Recipient Organization
    • 8.3.9. Regional Distribution of Grant Recipient Organization
    • 8.3.10. Prominent Project Leaders: Analysis by Number of Grants
    • 8.3.11. Emerging Focus Areas
    • 8.3.12. Grant Attractiveness Analysis

9. CASE STUDY: ADVANCED CRISPR-BASED TECHNOLOGIES / SYSTEMS AND TOOLS

  • 9.1. Chapter Overview
  • 9.2. CRISPR-based Technology Providers
    • 9.2.1. Analysis by Year of Establishment and Company Size
    • 9.2.2. Analysis by Geographical Location and Company Expertise
    • 9.2.3. Analysis by Focus Area
    • 9.2.4. Key Technology Providers: Company Snapshots
      • 9.2.4.1. APSIS Therapeutics
      • 9.2.4.2. Beam Therapeutics
      • 9.2.4.3. CRISPR Therapeutics
      • 9.2.4.4. Editas Medicine
      • 9.2.4.5. Intellia Therapeutics
      • 9.2.4.6. Jenthera Therapeutics
      • 9.2.4.7. KSQ Therapeutics
      • 9.2.4.8. Locus Biosciences
      • 9.2.4.9. Refuge Biotechnologies
      • 9.2.4.10. Repare Therapeutics
      • 9.2.4.11. SNIPR BIOME
    • 9.2.5. Key Technology Providers: Summary of Venture Capital Investments
  • 9.3. List of CRISPR Kit Providers
  • 9.4. List of CRISPR Design Tool Providers

10. POTENTIAL STRATEGIC PARTNERS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Potential Strategic Partners for Genome Editing Service Providers
    • 10.3.1. Key Industry Partners
      • 10.3.1.1. Most Likely Partners
      • 10.3.1.2. Likely Partners
      • 10.3.1.3. Less Likely Partners
    • 10.3.2. Key Non-Industry / Academic Partners
      • 10.3.2.1. Most Likely Partners
      • 10.3.2.2. Likely Partners
      • 10.3.2.3. Less Likely Partners

11. MARKET FORECAST

  • 11.1. Chapter Overview
  • 11.2. Forecast Methodology and Key Assumptions
  • 11.3. Overall CRISPR-based Genome Editing Services Market, 2019-2030
  • 11.4. CRISPR-based Genome Editing Services Market: Distribution by Regions, 2019-2030
    • 11.4.1. CRISPR-based Genome Editing Services Market in North America, 2019-2030
    • 11.4.2. CRISPR-based Genome Editing Services Market in Europe, 2019-2030
    • 11.4.3. CRISPR-based Genome Editing Services Market in Asia Pacific, 2019-2030
    • 11.4.4. CRISPR-based Genome Editing Services Market in Rest of the World, 2019-2030
  • 11.5. CRISPR-based Genome Editing Services Market: Distribution by Type of Services, 2019-2030
    • 11.5.1. CRISPR-based Genome Editing Services Market for gRNA Construction, 2019-2030
      • 11.5.1.1. CRISPR-based Genome Editing Services Market for gRNA Construction in North America, 2019-2030
      • 11.5.1.2. CRISPR-based Genome Editing Services Market for gRNA Construction in Europe, 2019-2030
      • 11.5.1.3. CRISPR-based Genome Editing Services Market for gRNA Construction in Asia Pacific, 2019-2030
      • 11.5.1.4. CRISPR-based Genome Editing Services Market for gRNA Construction in Rest of the World, 2019-2030
    • 11.6.1. CRISPR-based Genome Editing Services Market for Cell Line Engineering, 2019-2030
      • 11.6.1.1. CRISPR-based Genome Editing Services Market for Cell Line Engineering in North America, 2019-2030
      • 11.6.1.2. CRISPR-based Genome Editing Services Market for Cell Line Engineering in Europe, 2019-2030
      • 11.6.1.3. CRISPR-based Genome Editing Services Market for Cell Line Engineering in Asia Pacific, 2019-2030
      • 11.6.1.4.
    • 11.7.1. CRISPR-based Genome Editing Services Market for Animal Model Generation, 2019-2030
      • 11.7.1.1. CRISPR-based Genome Editing Services Market for Animal Model Generation in North America, 2019-2030
      • 11.7.1.2. CRISPR-based Genome Editing Services Market for Animal Model Generation in Europe, 2019-2030
      • 11.7.1.3. CRISPR-based Genome Editing Services Market for Animal Model Generation in Asia Pacific, 2019-2030
      • 11.7.1.4. CRISPR-based Genome Editing Services Market for Animal Model Generation in Rest of the World, 2019-2030
  • 11.8. CRISPR-based Genome Editing Services Market: Distribution by Type of Cell Line, 2019-2030
    • 11.8.1. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines, 2019-2030
      • 11.8.1.1. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines in North America, 2019-2030
      • 11.8.1.2. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines in Europe, 2019-2030
      • 11.8.1.3. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines in Asia Pacific, 2019-2030
      • 11.8.1.4. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines in Rest of the World, 2019-2030
    • 11.9.1. CRISPR-based Genome Editing Services Market for Microbial Cell Lines, 2019-2030
      • 11.9.1.1. CRISPR-based Genome Editing Services Market for Microbial Cell Lines in North America, 2019-2030
      • 11.9.1.2. CRISPR-based Genome Editing Services Market for Microbial Cell Lines in Europe, 2019-2030
      • 11.9.1.3. CRISPR-based Genome Editing Services Market for Microbial Cell Lines in Asia Pacific, 2019-2030
      • 11.9.1.4. CRISPR-based Genome Editing Services Market for Microbial Cell Lines in Rest of the World, 2019-2030
    • 11.10.1. CRISPR-based Genome Editing Services Market for Other Cell Lines, 2019-2030
      • 11.10.1.1. CRISPR-based Genome Editing Services Market for Other Cell Lines in North America, 2019-2030
      • 11.10.1.2. CRISPR-based Genome Editing Services Market for Other Cell Lines in Europe, 2019-2030
      • 11.10.1.3. CRISPR-based Genome Editing Services Market for Other Cell Lines in Asia Pacific, 2019-2030
      • 11.10.1.4. CRISPR-based Genome Editing Services Market for Other Cell Lines in Rest of the World, 2019-2030

12. SWOT ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. SWOT Analysis
    • 12.2.1. Strengths
    • 12.2.2. Weaknesses
    • 12.2.3. Opportunities
    • 12.2.4. Threats
    • 12.2.5. Concluding Remarks

13. EXECUTIVE INSIGHTS

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.